Determination of Mangiferin in Rat Eyes and Pharmacokinetic Study in Plasma After Oral Administration of Mangiferin-Hydroxypropyl-Beta-Cyclodextrin Inclusion

Purpose: To determine whether mangiferin can enter the eye, because the eye possesses the unique blood-ocular barrier. Methods: Due to the low solubility of mangiferin, hydroxypropyl-beta-cyclodextrin was applied to improve the absorbance. A reversed-phase high-performance liquid chromatography assay for mangiferin in rat plasma and eye fluid was developed. The mobile phase consisted of methanol-0.6% glacial acetic acid (27:73, v/v) at a flow rate of 1.0 mL/min. Results: Peak areas of mangiferin were linear over a concentration range of 0.40–20.00 μg/mL in blood samples and a range of 0.10–5.00 μg/mL in eye samples, respectively. Intra- and interassay precision and accuracy of mangiferin fell well within the predefined limits of acceptability (<15%). The recovery was 81.12%–87.18% in the plasma and 79.96%–85.52% in the eye, respectively. The analytical method had excellent sensitivity using a small sample volume (20 μL) with the lower limit of quantification, 0.4 and 0.10 μg/mL for plasma and eye, respectively. Pharmacokinetic parameters of mangiferin in plasma were obtained as follows: Tmax = 7 h, Cmax = (4.43 ± 0.62)μg/mL. The time point of 7 h was chosen for eye sample detection, as it had maximum plasma concentration. The concentration of mangiferin in the eye tissue 7 h after oral administration was (0.34 ± 0.13)μg/mL (n = 6), coefficient of variation % = 38.24%. Conclusions: Mangiferin can pass the blood-ocular barrier and is suitable to be used as an antioxidant in eye diseases.